EN
We Think That There Are Issues Underlying Fredun Pharmaceuticals' (NSE:FREDUN) Earnings
Despite posting some strong earnings, the market for Fredun Pharmaceuticals Limited's (NSE:FREDUN) stock hasn't moved much. Our analysis suggests that this might be because shareholders have noticed some concerning underlying factors.
A Closer Look At Fredun Pharmaceuticals' Earnings
As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF.
That means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".
Fredun Pharmaceuticals has an accrual ratio of 0.30 for the year to September 2026. Unfortunately, that means its free cash flow was a lot less than its statutory profit, which makes us doubt the utility of profit as a guide. In the last twelve months it actually had negative free cash flow, with an outflow of ₹788m despite its profit of ₹481.3m, mentioned above. We saw that FCF was ₹172m a year ago though, so Fredun Pharmaceuticals has at least been able to generate positive FCF in the past. Notably, the company has issued new shares, thus diluting existing shareholders and reducing their share of future earnings.
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Fredun Pharmaceuticals.
To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. Fredun Pharmaceuticals expanded the number of shares on issue by 17% over the last year. That means its earnings are split among a greater number of shares. Per share metrics like EPS help us understand how much actual shareholders are benefitting from the company's profits, while the net income level gives us a better view of the company's absolute size. Check out Fredun Pharmaceuticals' historical EPS growth by clicking on this link.
A Look At The Impact Of Fredun Pharmaceuticals' Dilution On Its Earnings Per Share (EPS)
Fredun Pharmaceuticals has improved its profit over the last three years, with an annualized gain of 269% in that time. In comparison, earnings per share only gained 233% over the same period. And at a glance the 75% gain in profit over the last year impresses. But in comparison, EPS only increased by 52% over the same period. Therefore, the dilution is having a noteworthy influence on shareholder returns.
In the long term, earnings per share growth should beget share price growth. So Fredun Pharmaceuticals shareholders will want to see that EPS figure continue to increase. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.
Our Take On Fredun Pharmaceuticals' Profit Performance
As it turns out, Fredun Pharmaceuticals couldn't match its profit with cashflow and its dilution means that earnings per share growth is lagging net income growth. For the reasons mentioned above, we think that a perfunctory glance at Fredun Pharmaceuticals' statutory profits might make it look better than it really is on an underlying level. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Every company has risks, and we've spotted 3 warning signs for Fredun Pharmaceuticals (of which 2 are a bit concerning!) you should know about.
In this article we've looked at a number of factors that can impair the utility of profit numbers, and we've come away cautious. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.